Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Diethylamine NONOate (DEA/NO) is a research-stage small molecule that acts as a nitric oxide (NO) donor. It belongs to the NONOate (diazeniumdiolate) class of compounds, which spontaneously release NO in aqueous solutions at a controlled, pH-dependent rate. DEA/NO is characterized by a relatively short half-life, ranging from approximately 2 to 16 minutes depending on temperature and pH, making it a valuable tool for studying the rapid biological effects of nitric oxide. Its primary biological activities include vasodilation through the activation of soluble guanylyl cyclase (sGC), antimicrobial action, and inhibition of the DNA repair enzyme O6-methylguanine-DNA-methyltransferase (MGMT) via S-nitrosylation. While it has been investigated in preclinical models for pulmonary hypertension and organ preservation, it is currently available only as a research reagent and is not approved for clinical use.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on diethylamine nonoate.